Black Women’s Perceptions of K-12 Experiences that Influenced their Preparation for College

This critical phenomenological inquiry explored the college preparation experiences of ten high-ability, Black, women who grew up in poverty to identify influences from various family, school, and community environments contributing to their college readiness. I used a conceptual framework informed by both Kimberlé Crenshaw’s (1991) intersectionality and Urie Bronfenbrenner’s (1979) ecological systems theory to frame this study and critically examine their responses. This specific paper reports 5 of the 9 themes that yielded from the inquiry: (1) prophetic excellence: family and friends support and expectations; (2) it takes a village: community culture and resources; (3) from chaperone to mentor: exploring the depth of K-12 academic relationships and experiences; (4) preparing for a home away from home: college exploration and preparation; (5) demystifying the process: I don\u27t know what I do or don\u27t need to know. Implications for anti-racist perspectives to inform the practices of counselor educators, school counselors, and school communities are discussed

Cross-Cultural Supervision: Racial/Ethnic Minority Supervisees\u27 Perspectives

Examining the clinical supervision experiences of minority supervisees with different backgrounds than their White supervisors is essential. Weak supervisory relationships can adversely affect a supervisee’s professional competency, which in turn can negatively influence the client. This study explored the experiences of ten Racial/ethnic minority supervisees in a cross-cultural supervision setting. Using consensual qualitative research (CQR), three domains emerged: (a) cultural sensitivity, (b) cultural competency, and (c) relationship building. The outcome of this study highlights the types of training in counselor education that supervisors should consider when working with supervisees from different cultural backgrounds

Preparing Doctoral Students to Succeed in Counselor Education Programs

Although many doctoral students in counselor education (CE) programs successfully complete their programs and obtain a doctoral degree, some students drop out for a variety of reasons (Protivnak & Foss, 2009). Given the negative consequences that accompany doctoral student attrition for non-completers and their university (Willis & Carmichael, 2011), scholars have begun to explore students’ experiences in CE doctoral programs (Hoskins & Goldberg, 2005; Protivnak & Foss, 2009). Despite the growing body of literature on students’ program experiences in CE doctoral programs, in general, little emphasis has been placed on how programs prepare students for success. In particular, to date, the literature related to how CE-sponsored programming orients students for doctoral training in CE is largely unknown. Such knowledge has the potential to shed light on student attrition and retention and further professional development issues in students. As such, this study aimed to fill this void by exploring aspects of CE doctoral student orientations and students’ perceptions of the degree to which these orientations met their needs

Cross-Cultural Supervision: Racial/Ethnic Minority Supervisees’ Perspectives

Examining the clinical supervision experiences of minority supervisees with different backgrounds than their White supervisors is essential. Weak supervisory relationships can adversely affect a supervisee’s professional competency, which in turn can negatively influence the client. This study explored the experiences of ten Racial/ethnic minority supervisees in a cross-cultural supervision setting. Using consensual qualitative research (CQR), three domains emerged: (a) cultural sensitivity, (b) cultural competency, and (c) relationship building. The outcome of this study highlights the types of training in counselor education that supervisors should consider when working with supervisees from different cultural backgrounds

The Human Phenotype Ontology in 2024: phenotypes around the world.

The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms. The HPO has widespread applications in clinical diagnostics and translational research, including genomic diagnostics, gene-disease discovery, and cohort analytics. In recent years, groups around the world have developed translations of the HPO from English to other languages, and the HPO browser has been internationalized, allowing users to view HPO term labels and in many cases synonyms and definitions in ten languages in addition to English. Since our last report, a total of 2239 new HPO terms and 49235 new HPO annotations were developed, many in collaboration with external groups in the fields of psychiatry, arthrogryposis, immunology and cardiology. The Medical Action Ontology (MAxO) is a new effort to model treatments and other measures taken for clinical management. Finally, the HPO consortium is contributing to efforts to integrate the HPO and the GA4GH Phenopacket Schema into electronic health records (EHRs) with the goal of more standardized and computable integration of rare disease data in EHRs

Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.

Early phase studies of alvocidib showed activity in relapsed CLL including patients with high risk genomic features and those refractory to fludarabine. A multi-center, international, phase II study of alvocidib in fludarabine refractory CLL was undertaken to validate these early results. Patients with fludarabine refractory CLL or prolymphocytic leukemia arising from CLL were treated with single agent alvocidib. The primary outcome measure was overall response rate, with secondary outcomes including survival, toxicity, and response duration. One hundred and sixty five patients were enrolled and 159 patients were treated. The median age was 61 years, the median number of prior therapies was 4, and 96% of patients were fludarabine refractory. The investigator-assessed overall response rate was 25%; the majority of responses were partial. Response rates were lower among patients with del(17p) (14%), but equivalent in patients with del(11q) or bulky lymphadenopathy. Median progression free and overall survival were 7.6 and 14.6 months, respectively. Tumor lysis occurred in 39 patients (25%), and 13 received hemodialysis. Diarrhea, fatigue, and hematologic toxicities were common. Alvocidib has clinical activity in patients with advanced, fludarabine refractory CLL. Future studies should focus on discovery of biomarkers of clinical response and tumor lysis, and enhanced supportive care measures

Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity

Importance: Ibrutinib has been associated with serious cardiotoxic arrhythmias. In preclinical models, these events are paralleled or proceeded by diffuse myocardial injury (inflammation and fibrosis). Yet whether this is seen in patients or has implications for future cardiotoxic risk is unknown. Objective: To assess the incidence and outcomes of myocardial injury among patients with ibrutinib-related cardiotoxicity. Design, setting, and participants: This cohort study included consecutive patients treated with ibrutinib from 2012 to 2019, phenotyped using cardiovascular magnetic resonance (CMR) from a large US Comprehensive Cancer Center registry. Exposures: Ibrutinib treatment for cancer control. Main outcomes and measures: The primary outcome was the presence of late gadolinium enhancement (LGE) fibrosis. The secondary outcome was the occurrence of major adverse cardiac events (MACE), defined as atrial fibrillation, heart failure, symptomatic ventricular arrhythmias, and sudden death of probable or definite ibrutinib association after CMR. We also assessed parametric-mapping subclinical fibrosis (native-T1, extracellular volume fraction) and inflammation/edema (max-T2) measures. Cardiovascular magnetic resonance measures were compared with those obtained in similar consecutive patients with cancer without ibrutinib treatment (pretreatment controls). Observed measures were also compared with similar-aged broad population rates (general-population controls) and a broader pool of cardiovascular disease (CVD) risk-matched cancer controls. Multivariable regression was used to assess the association between CMR measures and MACE. Results: Overall, 49 patients treated with ibrutinib were identified, including 33 imaged after treatment initiation (mean [SD] age, 65 [10] years, 9 [27%] with hypertension, and 23 [69.7%] with index-arrhythmias); median duration of ibrutinib-use was 14 months. The mean (SD) pretreatment native T1 was 977.0 (73.0) ms, max-T2 56.5 (4.0) ms, and 4 (13.3%) had LGE. Posttreatment initiation, mean (SD) native T1 was 1033.7 (48.2) ms, max-T2 61.5 (4.8) ms, and 17 (54.8%) had LGE (P < .001, P = .01, and P < .001, respectively, pre- vs post-ibrutinib treatment). Native T12SDs was elevated in 9 (28.6%), and max-T22SDs in 21 (63.0%), respectively. Cardiovascular magnetic resonance measures were highest in those with suspected toxic effects (P = .01 and P = .01, respectively). There was no association between traditional CVD-risk or cancer-treatment status and abnormal CMR measures. Among those without traditional CVD, 16 (58.6%) had LGE vs 38 (13.3%) in matched-controls (relative-risk, 4.8; P < .001). Over a median follow-up of 19 months, 13 (39.4%) experienced MACE. In multivariable models inclusive of traditional CVD risk factors, LGE (hazard ratio [HR], 4.9; P = .04), and native-T12SDs (HR, 3.3; P = .05) associated with higher risks of MACE. Conclusions and relevance: In this cohort study, myocardial injury was common in ibrutinib users, and its presence was associated with higher cardiotoxic risk